Cytek Biosciences, Inc. Free Cash Flow 2020–2025
Cytek Biosciences, Inc. reported $-8.77M of free cash flow for fiscal 2025. That was 140.1% lower than fiscal 2024. Compared with fiscal 2020, the change was -164.4%.
| Fiscal year | Free Cash Flow | Change (YoY) |
|---|---|---|
| FY 2025 | $-8.77M | -140.1% |
| FY 2024 | $21.85M | +3352.4% |
| FY 2023 | $633,000 | +102.9% |
| FY 2022 | $-21.98M | -8362.8% |
| FY 2021 | $266,000 | -98.0% |
| FY 2020 | $13.61M | — |
Source: Cytek Biosciences, Inc. SEC filings — cash flow statement (10-K). Computed deterministically; refreshed nightly (last updated August 2, 2026). Open CTKB 10-K filings at SEC EDGAR · Methodology · Download CSV.
How to read this history
Cytek Biosciences, Inc. reported $-8.77M of free cash flow for fiscal 2025. That was 140.1% lower than fiscal 2024. Compared with fiscal 2020, the change was -164.4%. Values remain missing when the cached filing does not disclose a comparable line item; they are never estimated. Stock splits, reorganizations and fiscal-calendar changes can reduce comparability.
Prepared and reviewed by the stockportfolio.pro research desk. Corrections: support@stockportfolio.pro.
See the full picture for Cytek Biosciences, Inc.
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeCytek Biosciences, Inc. — frequently asked questions
What is Cytek Biosciences, Inc.'s free cash flow?
Cytek Biosciences, Inc. (CTKB) reported free cash flow of $-8.77M for fiscal year 2025, per its SEC filings.
Where does this data come from?
Figures are computed from Cytek Biosciences, Inc.'s official SEC filings (cash flow statement (10-K)), refreshed nightly. Not investment advice.